Table 3.
Summary of Efficacy Measures Among Patients in the SOC + TNFerade Arm by TNFerade Delivery Method
| Outcome (months)* | EUS (n = 95) |
PTA (n = 91) |
HR† | 95% CI | P† | ||
|---|---|---|---|---|---|---|---|
| Median | 95% CI | Median | 95% CI | ||||
| Overall survival | 11.5 | 9.1 to 13.3 | 9.4 | 7.3 to 11.6 | 1.06 | 0.77 to 1.47 | .71 |
| Progression-free survival | 6.8 | 5.0 to 9.6 | 6.8 | 4.8 to 10.4 | 1.37 | 0.97 to 1.92 | .07 |
| Time to radiologic progression | 10.0 | 7.2 to 12.3 | 14.1 | 7.0 to 41.6 | 1.52 | 1.00 to 2.33 | .05 |
| Time to distant metastasis | 11.9 | 8.8 to 20.4 | 17.9 | 14.1 to N/A | 1.52 | 0.93 to 2.47 | .09 |
| Time to local progression | 16.5 | 11.8 to N/A | N/A | 18.5 to N/A | 1.99 | 0.92 to 4.32 | .08 |
Abbreviations: EUS, endoscopic ultrasound guided (transgastric/transduodenal approach); HR, hazard ratio; N/A, not achieved; PTA, percutaneous transabdominal approach; SOC, standard of care.
*
Median survival and times to progression were estimated by using the Kaplan-Meier method.
†
HR and corresponding P value were computed on the basis of a univariate Cox regression model.